Business Context and Reporting Period
This Form 8-K Current Report was filed by Calidi Biotherapeutics, Inc. (CLDI) on October 16, 2023, covering events occurring on October 10, 2023. The company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in San Diego, California.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the resignation of Dr. Heehyoung Lee from the Board of Directors and all associated committee positions, effective immediately on October 10, 2023.
Management Commentary and Risks
Management stated that Dr. Lee's resignation is for personal reasons. The company explicitly confirmed that the departure is not due to any disagreement with management or the Board regarding operations, policies, practices, or accounting policies. No new guidance, outlook, or unusual financial items were disclosed in this filing.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following Dr. Lee's departure.
- Confirm whether a successor director has been appointed to fill the vacancy.
- Review subsequent filings for any impact on committee structures or quorum requirements.